Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFNAEM)

• Drug Name: Sulfaphenazole Drug Info
• Synonyms: Sulfabid

Indication

Disease Entry	ICD 11	Status	REF
Bacterial infection	1A00-1C4Z	Approved	[1]

• Therapeutic Class: Antiinfective Agents
• Cross-matching ID:
  PubChem CID: 5335
  ChEBI ID: CHEBI:77780
  CAS Number: CAS 526-08-9
  TTD Drug ID: DMFNAEM
  VARIDT Drug ID: DR01009

Molecule-Related Drug Atlas

Drug(s) Affected By Cytochrome P450 1A2 (CYP1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[5]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[5]
Etoricoxib	DM6A4NW	Rheumatoid arthritis	FA20	Approved	[5]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[6]
Hesperetin	DMKER83	High blood cholesterol level	5C80.00	Approved	[7]
Stiripentol	DMMSDOY	Dravet syndrome	8A61.11	Approved	[8]
Nifedipine	DMSVOZT	Angina pectoris	BA40	Approved	[9]
Zileuton	DMVRIC2	Allergic asthma	CA23.0	Approved	[10]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[3]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[11]

Drug(s) Affected By Cytochrome P450 2C9 (CYP2C9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[12]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[13]
Dapsone	DM4LT8A	Acne vulgaris	ED80	Approved	[14]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[15]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[6]
Zafirlukast	DMHNQOG	Asthma	CA23	Approved	[16]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[14]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[17]
Fluconazole	DMOWZ6B	Cryptococcal meningitis		Approved	[15]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[14]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
S-mephenytoin 4-hydroxylase (CYP2C9)	TTR40YJ	CP2C9_HUMAN	Modulator	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cytochrome P450 1A2 (CYP1A2)	OTLLBX48	CP1A2_HUMAN	Gene/Protein Processing	[3]
Cytochrome P450 2C9 (CYP2C9)	OTGLBN29	CP2C9_HUMAN	Gene/Protein Processing	[4]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Identification of amino acid substitutions that confer a high affinity for sulfaphenazole binding and a high catalytic efficiency for warfarin meta... Biochemistry. 1998 Nov 17;37(46):16270-9.
• [3] Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem. 2005 Jun 2;48(11):3808-15.
• [4] Cytochrome P450 2C epoxygenases mediate photochemical stress-induced death of photoreceptors. J Biol Chem. 2014 Mar 21;289(12):8337-52. doi: 10.1074/jbc.M113.507152. Epub 2014 Feb 11.
• [5] In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. Basic Clin Pharmacol Toxicol. 2008 Aug;103(2):157-65.
• [6] Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
• [7] Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects. Toxicol Lett. 2018 Sep 15;294:27-36.
• [8] Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
• [9] Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
• [10] Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos. 2003 Nov;31(11):1352-60.
• [11] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [12] Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
• [13] Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos. 2003 Apr;31(4):439-46.
• [14] Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
• [15] The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
• [16] Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. Xenobiotica. 2004 May;34(5):429-38.
• [17] The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. Life Sci. 2006 Nov 25;79(26):2432-40.